FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL					
OMB	3235	5-			
Number:	010	4			
Expires:	November 30				
	201	1			
Estimated average					
burden hours per					
response	e 0.	5			

(1 filit of Type Responses)						
1. Name and Address of Reporting Person * Can-Fite BioPharma Ltd.	2. Date of Event Requiring Statement (Month/Day/Year)	3. Issuer Name and Ticker or Trading Symbol DENALI CONCRETE MANAGEMENT INC [DCMG]				
(Last) (First) (Middle) 1000 WINTER STREET, SUITE 2000	11/21/2011	Person(s) to I (Check	all applicable)	Filed(Month/Day/Year)		
(Street) WALTHAM, MA 02451		Director Officer (gi title below)	X 10% (ive Other below)	(specify 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person		
(City) (State) (Zip)	Table I - Non-Derivative Securities Beneficially Owned					
1.Title of Security (Instr. 4)	2. Amount of Beneficially ((Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)		
Common Stock	38,534,631		D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.	SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

(Instr. 4)	Expiration Date (Month/Day/Year)		Securities Underlying Derivative Security		or Exercise	5. Ownership Form of Derivative	6. Nature of Indirect Beneficial Ownership (Instr. 5)
		Expiration Date		Amount or Number of Shares	Derivative Security: Security Direct (D) or Indirect (I) (Instr. 5)		
Warrants	11/21/2011	<u>(1)</u>	Common Stock	2,160,102	\$ <u>(2)</u>	D	

Reporting Owners

Reporting Owner Name / Address		Relationships			
Reporting Owner Name / Nutress	Director	10% Owner	Officer	Other	
Can-Fite BioPharma Ltd. 1000 WINTER STREET, SUITE 2000 WALTHAM, MA 02451		X			

Signatures

Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

 Pursuant to a warrant agreement issued by Denali Concrete Management, Inc. (the "Company") to Can-Fite BioPharma, Ltd. ("Can-Fite") on November 21, 2011, Can-Fite shall have the right at any time to convert its warrants until the earlier of (a) the 5th-year anniversary
- (1) thereof and (b) the closing of the acquisition of the Company by another entity, resulting in the exchange of the outstanding shares of the Company's capital stock such that the stockholders of the Company prior to such transaction own, directly, or indirectly, less than 50% of the voting power of the surviving entity.
- Upon conversion, the per share purchase price for the shares of common stock will be as follows: (1) in the event that within 12 months of (2) November 21, 2011, the Company or any of its affiliates completes any transaction which has a "bio-dollar" value of more than \$100 million, then the par value of the shares of common stock, and (ii) at any other time, \$1.144.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.